Home
Contact Us
Log In
About Us
History
Facts & Figures
Network
Management Team
Investment Committee
Portfolio
Portfolio At A Glance
Neupogen / Neulasta
Remicade
Humira
Rituxan
Atripla / Truvada / Emtriva
Thalomid
Lyrica
Prezista
Letairis / Volibris
RotaTeq
Cubicin
Savella
Myozyme / Lumizyme
Lexiscan
Januvia / Janumet
Onglyza / Kombiglyze
Galvus / Eucreas
Nesina
Tradjenta
TOBI
Viviant
Cimzia
Mircera
Vosaroxin
Tecfidera
Conbriza/Aprela
Approach
Investment Criteria
Investment Process
Case Studies
Resource Center
Royalties Explained
Royalty Valuation
Royalty Market Overview
Benefits of Monetization
News & Events
Press Releases
Proposed Offer for Elan
Calendar of Events
15th Anniversary
Contact Us
Financing
Business Affairs/Legal
Investor Relations
Business Development
Address & Direction
Home
Site Map
Sitemap
About Us
History
Facts & Figures
Network
Management Team
Pablo Legorreta
Investment Committee
Rory Riggs
Approach
Investment Criteria
Investment Process
Case Studies
Resource Center
Royalties Explained
Royalty Valuation
Royalty Market Overview
Benefits of Monetization
News & Events
Press Releases
ROYALTY PHARMA INCREASES ALL CASH OFFER TO ACQUIRE ELAN TO $12.50 PER SHARE
ROYALTY PHARMA RULE 2.4 RELEASE REGARDING FORMAL CASH OFFER FOR ELAN
ROYALTY PHARMA RULE 2.4 RELEASE REGARDING ELAN DUTCH AUCTION RESULT
ROYALTY PHARMA ANNOUNCES FIRM FULLY FINANCED OFFER TO ACQUIRE ELAN
ROYALTY PHARMA STATEMENT REGARDING ELAN PROPOSAL
ROYALTY PHARMA PROPOSAL TO ACQUIRE ELAN CORPORATION, plc
ROYALTY PHARMA RAISES $600 MILLION OF DEBT
Royalty Pharma Announces $761 Million Acquisition of Interest in BG-12 and Fumaderm
Sunesis and Royalty Pharma Announce $25 Million Vosaroxin Royalty Agreement
Royalty Pharma Acquires Cimzia® and Mircera® Royalties for $124 million
Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million
Royalty Pharma Raises $3.6 Billion to Refinance $2.75 Billion of Outstanding Debt and to Fund an $850 Million Cash Distribution to Shareholders
Arisaph Pharmaceuticals and Royalty Pharma Announce Monetization and Amendment of DPP-IV License Agreement
Astellas’ Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty Pharma for $609 Million
Royalty Pharma Announces George Lloyd Joins Management Team
Royalty Pharma Acquires Lexiscan® and Cubicin® Royalties for $487 Million
Cypress Bioscience Agrees to be Acquired by Ramius LLC and Royalty Pharma for $6.50 per Share in Cash
Royalty Pharma Announces Alexander von Perfall Joins Management Team
Royalty Pharma Announces James Reddoch, PhD Joins Management Team
Royalty Pharma Acquires Royalty Interest in RotaTeq® from The Children’s Hospital Foundation for $182 Million
Royalty Pharma Acquires a Portion of Northwestern University’s Royalty Interest in Lyrica® for $700 Million
Royalty Pharma Acquires a Portion of New York University’s Royalty Interest in Remicade® for $650 Million
Royalty Pharma Announces Agreement Regarding the Purchase of the Rights to a Pre-Existing Royalty Interest in HUMIRA® from AstraZeneca and CAT
Emory Drug Deal Turns Heads
Royalty Pharma Acquires Memorial Sloan-Kettering Cancer Center’s International Royalty Interest in Neupogen® and Neulasta® for $142 Million
Gilead Sciences and Royalty Pharma Announce $525 Million Agreement with Emory University to Purchase Royalty Interest for Emtricitabine
Ligand, Royalty Pharma Amend SERM Royalty Agreement
Royalty Pharma Acquires a Portion of Memorial Sloan-Kettering Cancer Center’s US Royalty Interest in Neupogen/Neulasta
Ligand, Royalty Pharma Amend SERM Royalty Agreement
Standard & Poors - Royalty Pharma Finance Trust Rating AAA
Moody's Rates Royalty Pharma Pharmaceutical Royalty Securitization Aaa
Ligand, Royalty Pharma Expand SERM Royalty Agreement, Form New Royalty Partnership for Targretin Capsules
Ligand to Receive $3.5 Million as Royalty Pharma Exercises Another Option to Purchase Additional Rights to Future SERM Royalty Streams
Ligand to Receive $3 Million as Royalty Pharma Exercises First Option to Purchase Additional Rights to Future SERM Royalty Streams
Ligand, Royalty Pharma Conclude Agreement for Rights/Options Tied to Future SERM Royalty Streams
EntreMed Sells Thalidomide Royalty Stream for $24.3 Million
Xoma Receives $17 Million for Anti-CD20 Antibody Patents and Related Rights and $10 Million from Genentech for 1998 hu1124 Program
Proposed Offer for Elan
ROYALTY PHARMA INCREASES ALL CASH OFFER TO ACQUIRE ELAN TO $12.50 PER SHARE
ROYALTY PHARMA OFFER DOCUMENT REGARDING FORMAL CASH OFFER FOR ELAN
ROYALTY PHARMA RULE 2.4 RELEASE REGARDING FORMAL CASH OFFER FOR ELAN
ROYALTY PHARMA RULE 2.4 RELEASE REGARDING ELAN DUTCH AUCTION RESULT
ROYALTY PHARMA ANNOUNCES FIRM FULLY FINANCED OFFER TO ACQUIRE ELAN
ROYALTY PHARMA PRESENTATION REGARDING FIRM FULLY FINANCED OFFER FOR ELAN
ROYALTY PHARMA ANNOUNCES FIRM FULLY FINANCED OFFER TO ACQUIRE ELAN
ROYALTY PHARMA RESPONSE TO IRISH TAKEOVER PANEL ANNOUNCEMENT
ROYALTY PHARMA STATEMENT REGARDING ELAN PROPOSAL
ROYALTY PHARMA PRESENTATION REGARDING ELAN PROPOSAL
ROYALTY PHARMA PROPOSAL TO ACQUIRE ELAN CORPORATION, plc ("ELAN")
Calendar of Events
15th Anniversary
Contact Us
Financing
Business Affairs/Legal
Alex Kwit
George LLoyd
Investor Relations
Business Development
Jim Reddoch
Address & Direction
Site Map
Site Map
Site Map